Form 4: Director Charles Warden Receives Equity Grant at OCUL

Ocular Therapeutix director Charles M. Warden was granted 14,000 restricted stock units and 44,000 stock options on June 10, 2026.

Summary

• Director Charles M. Warden received an equity grant consisting of 14,000 restricted stock units (RSUs) and 44,000 stock options.
• The grant was issued under the company's 2021 Stock Incentive Plan.
• The stock options have an exercise price of $8.74 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment as it reflects standard corporate governance rather than a change in company strategy or financial health.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.
• The grant structure encourages long-term retention of board members.

Negatives

• The issuance of new equity results in potential dilution for existing shareholders.

Risks

• Continued service on the board is a prerequisite for the vesting of these equity awards.
• The value of the granted options is subject to market volatility and the future performance of the company's common stock.

Future Outlook

The equity awards are subject to vesting conditions based on continued board service, aligning the director's future incentives with the company's performance through June 2027 or the next annual meeting.

Management Comments

• The grants are subject to the reporting person's continued service on the Company's board of directors.

Industry Context

StockSavvy.ai notes that standard annual equity grants for board members in the biotechnology sector are common practice to ensure alignment with shareholder interests and to attract experienced leadership.

Comparison to Industry Standards

• The use of a 2021 Stock Incentive Plan is consistent with standard corporate governance practices for mid-cap biotech firms.
• Vesting schedules tied to annual meetings are standard practice for non-employee director compensation.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the RSUs and stock options on the first anniversary of the grant date or the next annual meeting of stockholders.

Key Dates

Keywords

OCUL, Ocular Therapeutix, Form 4, Insider Trading, Equity Compensation, Director Compensation